MicroRNA-301a (miR-301a) is induced in hepatocellular carcinoma (HCC) and down- regulates the expression of interferon regulatory factor-1.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
02 04 2020
Historique:
received: 09 12 2019
accepted: 05 01 2020
pubmed: 29 1 2020
medline: 21 10 2020
entrez: 29 1 2020
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) tumors evade death in part by downregulating expression of the tumor suppressor gene Interferon regulatory factor-1 (IRF-1). However, the molecular mechanisms accounting for IRF-1 suppression in HCC have not been well described. In this study, we identified a novel microRNA-301a (miR-301a) binding site in the 3'-untranslated region (3'- UTR) of the human IRF-1 gene and hypothesized a functional role for miR-301a in regulating HCC growth. We show that miR-301a is markedly upregulated in primary HCC tumors and HCC cell lines, while IRF-1 is down-regulated in a post-transcriptional manner. MiR-301a regulates basal and inducible IRF-1 expression in HCC cells with an inverse relationship between miR-301a and IRF-1 expression in HCC cells. Chronic hypoxia induces miR-301a in HCC in vitro and decreases IRF-1 expression. Finally, miR-301a inhibition increases apoptosis and decreases HCC cell proliferation. These findings suggest that targeting of IRF-1 by miR-301a contributes to the molecular basis for IRF-1 downregulation in HCC and provides new insight into the regulation of HCC by miRNAs.

Identifiants

pubmed: 31987500
pii: S0006-291X(20)30088-7
doi: 10.1016/j.bbrc.2020.01.034
pmc: PMC7857543
mid: NIHMS1662409
pii:
doi:

Substances chimiques

Interferon Regulatory Factor-1 0
MIRN301A microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-279

Subventions

Organisme : NLM NIH HHS
ID : HHSN276201200017C
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NIH HHS
ID : S10 OD019973
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA113263
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declared no conflict of interest with respect to this manuscript.

Références

Hepatology. 2010 Mar;51(3):881-90
pubmed: 20146264
Cell. 2009 Feb 20;136(4):642-55
pubmed: 19239886
Int J Cancer. 2008 Aug 15;123(4):972-8
pubmed: 18508316
Gene. 2014 Sep 10;548(1):91-100
pubmed: 25014136
J Interferon Cytokine Res. 2003 Sep;23(9):501-11
pubmed: 14565859
J Viral Hepat. 2012 Jul;19(7):473-9
pubmed: 22676359
Ann Surg Oncol. 2013 Jan;20(1):267-76
pubmed: 22805863
Oncoimmunology. 2012 Nov 1;1(8):1376-1386
pubmed: 23243601
J Interferon Cytokine Res. 2003 Nov;23(11):621-30
pubmed: 14651776
Molecules. 2014 May 19;19(5):6393-406
pubmed: 24853455
Cancer Lett. 2012 Jan 28;314(2):213-22
pubmed: 22056812
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5826-31
pubmed: 22451906
Oncogene. 2004 Feb 5;23(5):1125-35
pubmed: 14762441
Nature. 1996 Aug 29;382(6594):816-8
pubmed: 8752276
Clin Cancer Res. 2008 Jan 15;14(2):419-27
pubmed: 18223217
Mol Biosyst. 2015 Feb;11(2):532-9
pubmed: 25424171
Oncol Rep. 2016 Aug;36(2):633-40
pubmed: 27279136
Nucleic Acids Res. 2013 Mar 1;41(5):2817-31
pubmed: 23335783
Cancer Biol Ther. 2015;16(7):1029-41
pubmed: 26011589
Oncotarget. 2016 Apr 12;7(15):20953-65
pubmed: 26967567
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
Int J Cancer. 2007 Mar 1;120(5):1046-54
pubmed: 17149698
Cell Death Differ. 2010 Apr;17(4):699-709
pubmed: 19851330
Oncol Rep. 2017 Feb;37(2):945-952
pubmed: 28035415
J Gastroenterol. 2014 Feb;49(2):173-84
pubmed: 24258409
Biochem Biophys Res Commun. 2007 Oct 26;362(3):582-6
pubmed: 17723228
Oncogene. 2007 Sep 27;26(44):6420-30
pubmed: 17452973
Int J Clin Exp Pathol. 2015 May 01;8(5):5603-8
pubmed: 26191271

Auteurs

Kun Dong (K)

Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.

Qiang Du (Q)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Xiao Cui (X)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Peiqi Wan (P)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Christof Kaltenmeier (C)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Jing Luo (J)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Bing Yan (B)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

Yihe Yan (Y)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA.

David A Geller (DA)

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Electronic address: gellerda@upmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH